13th Edition of International Conference on Neurology and Brain Disorders
October 19-21, 2026
Corticobasal Syndrome (CBS)
Corticobasal Syndrome (CBS) is considered a relatively rare disorder, with an estimated incidence of 1-2 cases per million each year. The exact cause of CBS is unknown, although it is thought to be related to a genetic mutation in the MAPT gene, which is involved in the development and maintenance of white matter. Other potential risk factors include advancing age, head trauma, and autoimmune disorders. CBS is a progressive and ultimately fatal condition, with no approved treatment or cure. Most individuals with CBS will require physical, occupational, and speech therapy to help manage their symptoms, which can include difficulty with coordination, movement, and balance problems, as well as difficulty speaking, understanding, and remembering. Medication may be prescribed to reduce tremors, muscle spasms, and rigidity and to control pain and depression. Botox injections may be recommended to help reduce tremors and rigidity. Surgery may be appropriate in some cases to improve muscle contracture and relieve pressure on the compressed nerves. In addition, supportive treatments, such as nutritional and psychological support, and physical and occupational therapy can help optimize an individual's functional abilities.
Ken Ware
NeuroPhysics Therapy Institute and Research Centre, Australia
Yong Xiao Wang
Albany Medical College, United States
Joe Sam Robinson
Mercer University, United States
Daniel Curry
Texas Children’s Hospital, United States
Steven Benvenisti
Davis, Saperstein Salomon, PC, United States
Andrzej Stanislaw Cieplak
Independent researcher, United States
Younok Dumortier Shin
OnusBio, United StatesSubmit your abstract Today
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States